{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:37:16Z","timestamp":1778870236967,"version":"3.51.4"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journalofclinicalvirology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.jcv.2015.11.021","type":"journal-article","created":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T02:36:21Z","timestamp":1447900581000},"page":"S29-S39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"S1","title":["Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3216-7564","authenticated-orcid":false,"given":"Mario","family":"Poljak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"O\u0161trbenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Seme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"\u0160terbenc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Jan\u010dar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eda","family":"Vrta\u010dnik Bokal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2015.11.021_bib0005","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2008.11.046","article-title":"Papillomaviruses in the causation of human cancers\u2014a brief historical account","volume":"384","author":"Zur Hausen","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.jcv.2015.11.021_bib0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens\u2014 Part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol."},{"issue":"Suppl. 10","key":"10.1016\/j.jcv.2015.11.021_bib0015","doi-asserted-by":"crossref","first-page":"K29","DOI":"10.1016\/j.vaccine.2008.06.019","article-title":"Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries","volume":"26","author":"Cuzick","year":"2008","journal-title":"Vaccine"},{"issue":"Suppl. 5","key":"10.1016\/j.jcv.2015.11.021_bib0020","doi-asserted-by":"crossref","first-page":"F88","DOI":"10.1016\/j.vaccine.2012.06.095","article-title":"Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer","volume":"30","author":"Arbyn","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jcv.2015.11.021_bib0025","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.cmi.2015.05.041","article-title":"Towards cervical cancer eradication: joint force of HPV vaccination and HPV-based cervical cancer screening","volume":"21","author":"Poljak","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.jcv.2015.11.021_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2015.146","article-title":"HPV-FASTER broadening the scope for prevention of HPV-related cancer","author":"Bosch","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.jcv.2015.11.021_bib0035","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1386-6532(09)70002-2","article-title":"History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results","volume":"45","author":"Cox","year":"2009","journal-title":"J. Clin. Virol."},{"issue":"Suppl. 1","key":"10.1016\/j.jcv.2015.11.021_bib0040","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.jcv.2004.11.020","article-title":"The role of human papillomavirus testing in cervical screening","volume":"32","author":"Cuschieri","year":"2005","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2303.2005.00237.x","article-title":"The HPV test in cervical screening: a brave new world?","volume":"16","author":"Desai","year":"2005","journal-title":"Cytopathology"},{"key":"10.1016\/j.jcv.2015.11.021_bib0050","doi-asserted-by":"crossref","first-page":"687","DOI":"10.7326\/0003-4819-155-10-201111150-00376","article-title":"Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. preventive services task force","volume":"155","author":"Whitlock","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jcv.2015.11.021_bib0055","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ygyno.2014.12.022","article-title":"Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance","volume":"136","author":"Huh","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0060","doi-asserted-by":"crossref","first-page":"g130","DOI":"10.1136\/bmj.g130","article-title":"Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial","volume":"348","author":"Elfstr\u00f6m","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jcv.2015.11.021_bib0065","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2015.11.021_bib0070","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa073204","article-title":"Human papillomavirus and papanicolaou tests to screen for cervical cancer","volume":"357","author":"Naucler","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.11.021_bib0075","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(07)61450-0","article-title":"Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial","volume":"370","author":"Bulkmans","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2015.11.021_bib0080","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ijc.26056","article-title":"Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening","volume":"130","author":"Rijkaart","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jcv.2015.11.021_bib0085","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(09)70156-1","article-title":"HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial","volume":"10","author":"Kitchener","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0090","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(09)70360-2","article-title":"Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial","volume":"11","author":"Ronco","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0095","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1056\/NEJMoa0808516","article-title":"HPV screening for cervical cancer in rural India","volume":"360","author":"Sankaranarayanan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.11.021_bib0100","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/jnci\/djj209","article-title":"Human papillomavirus testing and liquid-based cytology in primary cervical screening: results at recruitment from the new technologies for cervical cancer randomized controlled trial","volume":"98","author":"Ronco","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jcv.2015.11.021_bib0105","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S1470-2045(06)70731-8","article-title":"Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial","volume":"7","author":"Ronco","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0110","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/jnci\/djp367","article-title":"Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting","volume":"101","author":"Leinonen","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jcv.2015.11.021_bib0115","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ijc.20076","article-title":"POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women","volume":"110","author":"Bulkmans","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jcv.2015.11.021_bib0120","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/bjc.2012.489","article-title":"Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial\u2014the HPV FOCAL study","volume":"107","author":"Ogilvie","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jcv.2015.11.021_bib0125","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa071430","article-title":"Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer","volume":"357","author":"Mayrand","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.11.021_bib0130","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1158\/1940-6207.CAPR-14-0409","article-title":"Five-year cervical (Pre) cancer risk of women screened by HPV and cytology testing","volume":"8","author":"Uijterwaal","year":"2015","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"10.1016\/j.jcv.2015.11.021_bib0135","doi-asserted-by":"crossref","first-page":"a1754","DOI":"10.1136\/bmj.a1754","article-title":"Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study","volume":"337","author":"Dillner","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jcv.2015.11.021_bib0140","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(11)70145-0","article-title":"Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice","volume":"12","author":"Katki","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0145","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/jnci\/95.1.46","article-title":"Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: acohort 10-year analysis","volume":"95","author":"Sherman","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"issue":"Suppl. 1","key":"10.1016\/j.jcv.2015.11.021_bib0150","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1097\/LGT.0b013e318285423c","article-title":"Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines","volume":"17","author":"Katki","year":"2013","journal-title":"J. Low Genit. Tract. Dis."},{"key":"10.1016\/j.jcv.2015.11.021_bib0155","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.2011.38.8389","article-title":"Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up","volume":"30","author":"Castle","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0160","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/ijc.29381","article-title":"Primary human papillomavirus DNA screening for cervical cancer prevention: can the screening interval be safely extended?","volume":"137","author":"Vink","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jcv.2015.11.021_bib0165","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju153","article-title":"Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test","volume":"106","author":"Gage","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jcv.2015.11.021_bib0170","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/sj.bjc.6600918","article-title":"Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients","volume":"88","author":"Petry","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jcv.2015.11.021_bib0175","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/bmj.325.7364.572","article-title":"Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study","volume":"325","author":"Kjaer","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jcv.2015.11.021_bib0180","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/ijc.23339","article-title":"Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-results from the Hammersmith study","volume":"122","author":"Cuzick","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jcv.2015.11.021_bib0185","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1054\/bjoc.2001.1845","article-title":"Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women","volume":"84","author":"Clavel","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jcv.2015.11.021_bib0190","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/01.OLQ.0000080177.82204.E0","article-title":"Cervical human papillomavirus infection in the female population in Barcelona, Spain","volume":"30","author":"de Sanjose","year":"2003","journal-title":"Sex Transm. Dis."},{"key":"10.1016\/j.jcv.2015.11.021_bib0195","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ajog.2005.01.056","article-title":"Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence","volume":"193","author":"Elfgren","year":"2005","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"447","key":"10.1016\/j.jcv.2015.11.021_bib0200","first-page":"e1","article-title":"Human papillomavirus and papanicolaou tests screening interval recommendations in the United States","volume":"205","author":"Roland","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/GCO.0b013e32835c5d10","article-title":"Primary human papillomavirus testing in organized cervical screening","volume":"25","author":"Dillner","year":"2013","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0210","article-title":"Commercially available molecular tests for human papillomaviruses (HPV)-2015 update","author":"Poljak","year":"2015","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0215","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cmi.2015.04.015","article-title":"Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?","volume":"21","author":"Arbyn","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.jcv.2015.11.021_bib0220","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.24010","article-title":"Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older","volume":"124","author":"Meijer","year":"2009","journal-title":"Int. J. Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.jcv.2015.11.021_bib0225","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S1386-6532(09)70005-8","article-title":"HPV High-risk detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test","volume":"45","author":"Tang","year":"2009","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0230","first-page":"43","article-title":"HPV The Abbott RealTime High Risk test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies","volume":"22","author":"Poljak","year":"2013","journal-title":"Acta Dermatovenerol. Alp. Pannonica Adriat."},{"key":"10.1016\/j.jcv.2015.11.021_bib0235","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1128\/JCM.02311-10","article-title":"Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of Hybrid Capture 2 assay in a screening setting","volume":"49","author":"Carozzi","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0240","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1128\/JCM.00012-11","article-title":"Comparison of clinical and analytical performance of the Abbott RealTime High Risk HPV test and Hybrid Capture 2 in population-based cervical cancer screening","volume":"49","author":"Poljak","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0245","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1128\/JCM.00633-13","article-title":"Clinical validation of the Abbott RealTime High Risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening","volume":"51","author":"Hesselink","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0250","unstructured":"Society for gynecological oncology, colposcopy and cervical pathology, Slovenian guidelines for management of pathological cervical smears, M. Ur\u0161i\u010d Vr\u0161\u010daj (Ed.), in Slovene: Zdru\u017eenje za ginekolo\u0161ko onkologijo, kolposkopijo in cervikalno patologijo. Smernice za celostno obravnavo \u017eensk s predrakavimi spremembami materni\u010dnega vratu. Available at: http:\/\/zora.onko-i.si\/fileadmin\/user_upload\/dokumenti\/strokovna_priporocila\/2011_Smernice_web.pdf (accessed 25.9.15)."},{"key":"10.1016\/j.jcv.2015.11.021_bib0255","first-page":"94","article-title":"The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2HPV DNA test","volume":"18","author":"Poljak","year":"2009","journal-title":"Acta Dermatovenerol. Alp. Panonica Adriat."},{"key":"10.1016\/j.jcv.2015.11.021_bib0260","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcv.2010.05.008","article-title":"Evaluation of the clinical performance of the Abbott RealTime high-Risk HPV for carcinogenic HPV detection","volume":"48","author":"Halfon","year":"2010","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0265","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jcv.2011.10.016","article-title":"Comparison of Abbott RealTime High Risk HPV and Hybrid Capture 2 for the detection of high-risk HPV DNA in a referral population setting","volume":"53","author":"Venturoli","year":"2012","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0270","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1097\/IGC.0b013e31825529b7","article-title":"Evaluation of a new multiplex real-time polymerase chain reaction assay for the detection of human papillomavirus infections in a referral population","volume":"22","author":"Jentschke","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.jcv.2015.11.021_bib0275","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/JCM.00337-12","article-title":"Comparison of the Abbott RealTime High-Risk human papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA","volume":"50","author":"Park","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0280","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3343\/alm.2012.32.3.201","article-title":"Comparison of the AdvanSure human papillomavirus screening real-time PCR, the Abbott RealTime High Risk human papillomavirus test, and the Hybrid Capture human papillomavirus DNA test for the detection of human papillomavirus","volume":"32","author":"Hwang","year":"2012","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.jcv.2015.11.021_bib0285","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3233\/CBM-2010-0156","article-title":"Stepwise algorithm combining HPV high-risk DNA-based assays and RNA-based assay for high grade CIN in women with abnormal smears referred to colposcopy","volume":"7","author":"Halfon","year":"2010","journal-title":"Cancer Biomark"},{"issue":"Suppl. 1","key":"10.1016\/j.jcv.2015.11.021_bib0290","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1386-6532(09)70003-4","article-title":"Principles and analytical performance of Abbott RealTime High Risk HPV test","volume":"45","author":"Huang","year":"2009","journal-title":"J. Clin. Virol."},{"issue":"Suppl. 1","key":"10.1016\/j.jcv.2015.11.021_bib0295","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S1386-6532(09)70004-6","article-title":"Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology","volume":"45","author":"Huang","year":"2009","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0300","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/jmv.21801","article-title":"Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears","volume":"82","author":"Cuzick","year":"2010","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0305","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jcv.2011.03.010","article-title":"Efficacy of Abbott RealTime High Risk HPV test in evaluation of atypical squamous cells of undetermined significance from an Asian screening population","volume":"51","author":"Wong","year":"2011","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0310","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1128\/JCM.00181-12","article-title":"Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the predictors 2 study","volume":"50","author":"Szarewski","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0315","first-page":"47","article-title":"Pre-vaccination distribution of human papillomavirus (HPV) genotypes in women with cervical intraepithelial neoplasia grade 3 (CIN 3) lesions in Slovenia","volume":"18","author":"Kovanda","year":"2009","journal-title":"Acta Dermatovenerol. Alp. Panonica Adriat."},{"key":"10.1016\/j.jcv.2015.11.021_bib0320","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/aogs.12686","article-title":"High risk HPV testing in the triage of repeat ASC-US and LSIL","volume":"94","author":"Veijalainen","year":"2015","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.jcv.2015.11.021_bib0325","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jviromet.2013.08.036","article-title":"Comparison of the detection of HPV-16, 18, 31, 33, and 45 by type-specific DNA- and E6\/E7 mRNA-based assays of HPV DNA positive women with abnormal Pap smears","volume":"194","author":"Salimovi\u0107-Be\u0161i\u0107","year":"2013","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jcv.2015.11.021_bib0330","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/bjc.2013.22","article-title":"Comparing the performance of six human papillomavirus tests in a screening population","volume":"108","author":"Cuzick","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jcv.2015.11.021_bib0335","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jviromet.2014.04.021","article-title":"Comparison of the clinical performances of the AdvanSure HPV screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for cervical cancer screening","volume":"205C","author":"Chung","year":"2014","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jcv.2015.11.021_bib0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2015.08.011","article-title":"Comparative evaluation of two vaginal self-sampling devices for the detection of human papillomavirus infections","author":"Jentschke","year":"2015","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0345","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12985-014-0234-8","article-title":"Identification of human papillomaviruses from formalin-fixed, paraffin-embedded pre-cancer and invasive cervical cancer specimens in Zambia: a cross-sectional study","volume":"12","author":"Bateman","year":"2015","journal-title":"Virol. J."},{"key":"10.1016\/j.jcv.2015.11.021_bib0350","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jviromet.2011.04.006","article-title":"Comparison of the Abbott RealTime High Risk HPV test and INNO-LiPA HPV genotyping extra test for the detection of human papillomaviruses in formalin-fixed, paraffin-embedded cervical cancer specimens","volume":"175","author":"Kocjan","year":"2011","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jcv.2015.11.021_bib0355","first-page":"73","article-title":"Comparative evaluation of the Abbott RealTime High Risk HPV test and INNO-LiPA HPV genotyping extra test for detecting and identifying human papillomaviruses in archival tissue specimens of head and neck cancers","volume":"21","author":"Kocjan","year":"2012","journal-title":"Acta Dermatovenerol. Alp. Panonica Adriat."},{"key":"10.1016\/j.jcv.2015.11.021_bib0360","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jviromet.2013.05.009","article-title":"Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples","volume":"193","author":"Jentschke","year":"2013","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jcv.2015.11.021_bib0365","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/CEJ.0000000000000100","article-title":"Comparative analysis of cervical cytology and human papillomavirus genotyping by three different methods in a routine diagnostic setting","volume":"24","author":"Padalko","year":"2015","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.jcv.2015.11.021_bib0370","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.diagmicrobio.2013.04.012","article-title":"Comparison of the analytical and clinical performances of Abbott RealTime High Risk HPV, Hybrid Capture 2, and DNA chip assays in gynecology patients","volume":"76","author":"Park","year":"2013","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.jcv.2015.11.021_bib0375","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jviromet.2012.09.005","article-title":"Detection and genotyping of human papillomavirus by five assays according to cytologic results","volume":"187","author":"Choi","year":"2013","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jcv.2015.11.021_bib0380","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/apm.12054","article-title":"Comparison of the Abbott RealTime High Risk HPV with genomica HPV clinical array for the detection of human papillomavirus DNA","volume":"121","author":"Sias","year":"2013","journal-title":"APMIS"},{"key":"10.1016\/j.jcv.2015.11.021_bib0385","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/cyt.12046","article-title":"Effect of glacial acetic acid pre-treatment of cervical liquid-based cytology specimens on the molecular detection of human papillomavirus","volume":"24","author":"Moore","year":"2013","journal-title":"Cytopathology"},{"key":"10.1016\/j.jcv.2015.11.021_bib0390","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/jclinpath-2013-202014","article-title":"Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H)","volume":"67","author":"Cubie","year":"2014","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0395","article-title":"Improving laboratory efficiency by automation of preanalytic processing of ThinPrep specimens for real-time PCR high-risk HPV testing","author":"Barbieri","year":"2015","journal-title":"J. Lab. Autom."},{"key":"10.1016\/j.jcv.2015.11.021_bib0400","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.vaccine.2011.10.066","article-title":"Pre-vaccination prevalence and distribution of high-risk human papillomavirus (HPV) types in Slovenian women: a cervical cancer screening based study","volume":"30","author":"U\u010dakar","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jcv.2015.11.021_bib0405","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/jmv.23997","article-title":"Pre-vaccination prevalence of infections with 25 non-high-risk human papillomavirus types among 1000 Slovenian women in cervical cancer screening","volume":"86","author":"U\u010dakar","year":"2014","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0410","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1016\/j.vaccine.2013.08.038","article-title":"Pre-vaccination seroprevalence of 15 human papillomavirus (HPV) types among women in the population-based Slovenian cervical screening program","volume":"31","author":"U\u010dakar","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jcv.2015.11.021_bib0415","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jcv.2012.12.004","article-title":"Serum antibodies to human papillomaviruses (HPV) pseudovirions correlate with natural infection for 13 genital HPV types","volume":"56","author":"Faust","year":"2013","journal-title":"J. Clin. Virol."},{"issue":"Suppl. 7","key":"10.1016\/j.jcv.2015.11.021_bib0420","doi-asserted-by":"crossref","first-page":"H80","DOI":"10.1016\/j.vaccine.2013.04.038","article-title":"Recommendations for cervical cancer prevention in Central and Eastern Europe and Central Asia","volume":"31","author":"Poljak","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jcv.2015.11.021_bib0425","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1158\/1055-9965.EPI-12-0181","article-title":"Cervical cancer burden and prevention activities in Europe","volume":"21","author":"Kesic","year":"2012","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.jcv.2015.11.021_bib0430","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ijc.21955","article-title":"Overview of the European and North American studies on HPV testing in primary cervical cancer screening","volume":"119","author":"Cuzick","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"Suppl. 3","key":"10.1016\/j.jcv.2015.11.021_bib0435","article-title":"Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses","volume":"24","author":"Arbyn","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.jcv.2015.11.021_bib0440","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/oxfordjournals.jncimonographs.a003488","article-title":"Chapter 13: Primary screening of cervical cancer with human papillomavirus tests","volume":"31","author":"Franco","year":"2003","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"10.1016\/j.jcv.2015.11.021_bib0445","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ygyno.2014.11.076","article-title":"Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test","volume":"136","author":"Wright","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0450","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1309\/AJCPHVD7MIP3FYVV","article-title":"Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study","volume":"144","author":"Reid","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0455","article-title":"A review of the clinical performance of the Aptima HPV assay","author":"Haedicke","year":"2015","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.pvr.2015.06.006","article-title":"European guidelines for quality assurance in cervical cancers screening. Summary of the supplements on HPV screening and vaccination","author":"von Karsa","year":"2015","journal-title":"Papillomavirus Res."},{"issue":"Suppl. 5","key":"10.1016\/j.jcv.2015.11.021_bib0465","doi-asserted-by":"crossref","first-page":"F107","DOI":"10.1016\/j.vaccine.2012.05.088","article-title":"New technologies and procedures for cervical cancer screening","volume":"30","author":"Cuzick","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jcv.2015.11.021_bib0470","article-title":"Triage of HPV positive women in cervical cancer screening","author":"Wentzensen","year":"2015","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0475","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/JCM.02116-14","article-title":"A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results","volume":"53","author":"Schiffman","year":"2015","journal-title":"J. Clin. Microbiol."},{"issue":"184","key":"10.1016\/j.jcv.2015.11.021_bib0480","first-page":"e1","article-title":"Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16\/18: results from the ATHENA HPV study","volume":"208","author":"Cox","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0485","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1470-2045(14)70019-1","article-title":"Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial","volume":"15","author":"Verhoef","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0490","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S1470-2045(12)70529-6","article-title":"Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial","volume":"14","author":"Carozzi","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0495","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ygyno.2011.02.033","article-title":"Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16\/Ki-67 dual-stained cytology","volume":"121","author":"Petry","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jcv.2015.11.021_bib0500","article-title":"Attitudes of changes in cervical screening: views of Australian general practitioners and nurses","author":"Denham","year":"2015","journal-title":"J. Clin. Virol"},{"key":"10.1016\/j.jcv.2015.11.021_bib0505","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ijc.29374","article-title":"Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology","volume":"137","author":"Thomsen","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jcv.2015.11.021_bib0510","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/ijc.29085","article-title":"HPV long-term type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial","volume":"136","author":"Smelov","year":"2015","journal-title":"Int. J. Cancer"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653215007556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653215007556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T15:02:54Z","timestamp":1718204574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653215007556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":102,"alternative-id":["S1386653215007556"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2015.11.021","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2015.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}